Brought to you by:
Rethinking antiplatelet and anticoagulant use in PAD after AQUATIC
During Thursday’s Hot Topics session, John Curci, MD, an associate professor at Vanderbilt Health, discussed the changing landscape of long-term antiplatelet and anticoagulant use in the management of peripheral artery disease (PAD) in light of results from the AQUATIC trial.…
High level of heterogeneity found in randomized PAD trial antithrombotic regimens
A recent systematic review showed that randomized trials comparing different types of peripheral endovascular arterial intervention have a high level of heterogeneity in their antithrombotic regimens. It also revealed an increasing trend for use of dual antiplatelet therapy post intervention…